Literature DB >> 17700563

MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas.

Judith W M Jeuken1, Sandra J B Cornelissen, Martine Vriezen, Marieke M G Dekkers, Abdellatif Errami, Angelique Sijben, Sandra H E Boots-Sprenger, Pieter Wesseling.   

Abstract

Expression of the DNA repair protein O6-alkylguanine-DNA-alkyltransferase (AGT), encoded by the O6-methylguanine (O6-mG) -DNA-methyltransferase (MGMT) DNA repair gene, results in resistance to alkylating agents, and hypermethylation of the MGMT promoter is associated with chemosensitivity as it prevents AGT expression. As the interpretation of the results of immunohistochemistry to evaluate AGT expression proved to be difficult, the aim of our present study is to establish a feasible, reliable, and robust method for MGMT promoter hypermethylation testing that can be easily implemented in a diagnostic setting and is applicable to routinely processed tissue. MGMT hypermethylation analysis using methylation-specific (MS-) multiplex ligation-dependent probe amplification (MLPA) was performed on 62 glioma samples of 55 individual tumors (including 12 cell lines) and compared to the more conventionally used, but improved, MS-polymerase chain reaction (PCR). In contrast to MS-PCR, MS-MLPA (i) is not based on bisulfite conversion of unmethylated cytosines (a somewhat troublesome step in MS-PCR), (ii) provided methylation status of all samples, (iii) proved to be semiquantitative, (iv) can be used to evaluate methylation status of multiple sequences (CpG dinucleotides) simultaneously, and (v) allows for a combined copy number detection and methylation specific analysis. The potential therapeutic value of MGMT hypermethylation evaluation using MS-MLPA was shown in a group of 20 glioblastoma patients receiving temozolomide chemotherapy. We conclude that MS-MLPA is a robust and reliable method that can be easily applied to differently processed tissues, including those fixed in formalin and embedded in paraffin. The semiquantitative aspect of MS-MLPA may prove to be of great value, especially in predicting response to alkylating agents, not only for gliomas as evaluated in this study but also for tumors in general.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17700563     DOI: 10.1038/labinvest.3700664

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  76 in total

1.  Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.

Authors:  Chul-Kee Park; JinWook Kim; Su Youn Yim; Ah Reum Lee; Jung Ho Han; Chae-Yong Kim; Sung-Hye Park; Tae Min Kim; Se-Hoon Lee; Seung Hong Choi; Seung-Ki Kim; Dong Gyu Kim; Hee-Won Jung
Journal:  Neuro Oncol       Date:  2010-11-12       Impact factor: 12.300

2.  MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.

Authors:  Mireia Gausachs; Pilar Mur; Julieta Corral; Marta Pineda; Sara González; Llúcia Benito; Mireia Menéndez; Josep Alfons Espinàs; Joan Brunet; María Dolores Iniesta; Stephen B Gruber; Conxi Lázaro; Ignacio Blanco; Gabriel Capellá
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

3.  Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA.

Authors:  Gabriella Livide; Maria Carmela Epistolato; Mariangela Amenduni; Vittoria Disciglio; Annabella Marozza; Maria Antonietta Mencarelli; Paolo Toti; Stefano Lazzi; Theodora Hadjistilianou; Sonia De Francesco; Alfonso D'Ambrosio; Alessandra Renieri; Francesca Ariani
Journal:  Pathol Oncol Res       Date:  2012-01-26       Impact factor: 3.201

4.  Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study.

Authors:  Lars Henrik Jensen; Anders Aamann Rasmussen; Lene Byriel; Hidekazu Kuramochi; Dorthe Gylling Crüger; Jan Lindebjerg; Peter V Danenberg; Anders Jakobsen; Kathleen Danenberg
Journal:  Cell Oncol (Dordr)       Date:  2013-09-12       Impact factor: 6.730

5.  Primer extension based quantitative polymerase chain reaction reveals consistent differences in the methylation status of the MGMT promoter in diffusely infiltrating gliomas (WHO grade II-IV) of adults.

Authors:  Erik Vassella; Istvan Vajtai; Nora Bandi; Marlene Arnold; Verena Kocher; Luigi Mariani
Journal:  J Neurooncol       Date:  2010-12-22       Impact factor: 4.130

6.  Analysis of microsatellite instability in medulloblastoma.

Authors:  Marta Viana-Pereira; Inês Almeida; Sónia Sousa; Bethânia Mahler-Araújo; Raquel Seruca; José Pimentel; Rui Manuel Reis
Journal:  Neuro Oncol       Date:  2009-01-29       Impact factor: 12.300

7.  Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma.

Authors:  K L Rankeillor; D A Cairns; C Loughrey; S C Short; P Chumas; A Ismail; A Chakrabarty; S E Lawler; P Roberts
Journal:  J Neurooncol       Date:  2014-02-20       Impact factor: 4.130

8.  MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

Authors:  Martin J van den Bent; Hendrikus J Dubbink; Marc Sanson; Cathleen R van der Lee-Haarloo; Monika Hegi; Judith W M Jeuken; Ahmed Ibdaih; Alba A Brandes; Martin J B Taphoorn; Marc Frenay; Denis Lacombe; Thierry Gorlia; Winand N M Dinjens; Johan M Kros
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

9.  MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.

Authors:  S Trabelsi; N Mama; M Ladib; N Karmeni; M Haddaji Mastouri; M Chourabi; M Mokni; K Tlili; H Krifa; M T Yacoubi; A Saad; D H'mida Ben Brahim
Journal:  Clin Transl Oncol       Date:  2015-08-20       Impact factor: 3.405

10.  The Changes in MGMT Promoter Methylation Status in Initial and Recurrent Glioblastomas.

Authors:  Chul-Kee Park; Ja Eun Kim; Ji Young Kim; Sang Woo Song; Jin Wook Kim; Seung Hong Choi; Tae Min Kim; Se-Hoon Lee; Il Han Kim; Sung-Hye Park
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.